Mol. Cells 2021; 44(5): 363~373  https://doi.org/10.14348/molcells.2021.0044
Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
Yong Jun Lee 1,4, Jii Bum Lee 1,2,4, Sang-Jun Ha 3,*, and Hye Ryun Kim 1,*
1Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Korea, 2Division of Hemato-oncology, Wonju Severance Christian Hospital, Yonsei University College of Medicine, Wonju 26426, Korea, 3Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul 03722, Korea, 4These authors contributed equally to this work.
Received February 25, 2021; Revised March 22, 2021; Accepted March 23, 2021.; Published online May 17, 2021.
© Korean Society for Molecular and Cellular Biology. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-sa/3.0/).
ABSTRACT
Immune checkpoint inhibitors have changed the paradigm of treatment options for non-small cell lung cancer (NSCLC). Monoclonal antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have gained wide attention for their application, which has been shown to result in prolonged survival. Nevertheless, only a limited subset of patients show partial or complete response to PD-1 therapy, and patients who show a response eventually develop resistance to immunotherapy. This article aims to provide an overview of the mechanisms of acquired resistance to anti–PD-1/PD-L1 therapy from the perspective of tumor cells and the surrounding microenvironment. In addition, we address the potential therapeutic targets and ongoing clinical trials, focusing mainly on NSCLC.
Keywords: acquired resistance, immune checkpoint inhibitors, non-small cell lung cancer, programmed death-1, programmed death ligand-1
INTRODUCTION

Immune checkpoint inhibitors (ICIs) that target cytotoxic T lymphocyte associated antigen-4 (CTLA-4), PD-1, and PD-L1 receptors have been shown to have beneficial therapeutic effects in lung cancer (Steven et al., 2016). ICIs are the first-line treatment for non-small cell lung cancer (NSCLC) with positive PD-L1 expression (Ettinger et al., 2019). However, only 20% to 30% of NSCLC patients are sensitive to anti–PD-1/PD-L1 therapy, and most patients experience resistance to immunotherapy (Pourmir et al., 2020). Acquired resistance is defined as disease progression within 6 months after a period of clinical benefit (Remon et al., 2020; Sharma et al., 2017). The mechanisms of acquired resistance remain to be fully elucidated, as research on treatment strategies to overcome resistance to approved immunotherapies is ongoing (Bagchi et al., 2021). Here, we discuss the mechanisms of acquired resistance to anti–PD-1/PD-L1 therapy in NSCLC, including loss of immunogenic neoantigens, upregulation of alternate immune checkpoint receptors, increase in immunosuppressive cells, cytokines, and immunoregulatory molecules in the tumor microenvironment, and epigenetic modifications. In addition, we have summarized the potential therapeutic targets and ongoing clinical trials.

MECHANISMS OF ACQUIRED RESISTANCE TO ANTI–PD-1/PD-L1

Loss of immunogenic neoantigen

B2M and MHC defects

Defects in beta-2-microglobulin (B2M) or major histocompatibility complex (MHC) molecules can cause decreased neoantigen presentation (Mariathasan et al., 2018; Sucker et al., 2014). B2M stabilizes the alpha subunits of the MHC-I protein, and a mutation in the B2M gene results in loss of neoantigen surface expression (Gettinger et al., 2017; Zaretsky et al., 2016). In NSCLC, acquired homozygous loss of B2M results in a lack of MHC-I expression on the cell surface, which results in acquired resistance to PD-1 therapy (Gettinger et al., 2017). In addition to loss of heterozygosity, deletions or point mutations in the B2M gene have been found to be important pathways for both primary and acquired resistance to ICIs (Gettinger et al., 2017; Pereira et al., 2017).

Defects in the IFN-γpathway

Activated T cells and natural killer (NK) T cells release interferon-gamma (IFN-γ) into the tumor microenvironment and affect immune reactions through the downstream enzymes Janus kinase 1 and 2 (JAK1 and JAK2) and signal transducer and activators of transcription (STATs) (Taube et al., 2012). IFN-γ stimulates antigen production, upregulation of PD-L1 expression in tumor cells, and production of T cell-attracting chemokines (Abiko et al., 2015). Deficiencies in IFN-γ, JAK1/2, or STATs prevent IFN-γ signaling and consequently result in downregulation of T cell infiltration, and decrease in PD-L1 and MHC-I expression (Bach et al., 1997; Sucker et al., 2017). In patients with melanoma, JAK1- or JAK2-inactivating mutations lead to acquired resistance to anti–PD-1 therapy via inhibition of the IFN-γ pathway and PD-L1 expression (Shin et al., 2017). Loss of PD-L1 expression is associated with less effective PD-1 blocking (Ren et al., 2020). Other IFN-γ pathway-related gene mutations, such as deletion of IFN-γ receptor 1 and 2 (IFNGR1 and 2), STAT2, JAK1, and JAK2, also result in acquired resistance in melanoma (Manguso et al., 2017; Ren et al., 2020).

Targeting downstream factors, such as JAK1/2 and STAT, is a possible treatment option to overcome acquired resistance to anti–PD-1 therapy in lung cancer (Table 1). A combination of JAK-STAT or vascular endothelial growth factor (VEGF) inhibitors and immune checkpoint therapy can help control tumor growth in phosphatase and tensin homolog (PTEN)-mediated acquired resistance to immune checkpoint monotherapy (Peng et al., 2016; Toso et al., 2014). Dual inhibition of the JAK1,2/PD-L1 and STAT3/PD-L1 signaling pathways led to better immune cytolytic activity of NK cells toward hypoxia-induced castrate-resistant prostate cancer (CRPC) cells (Xu et al., 2018). However, the combination of anti–PD-1 therapy with JAK/STAT inhibitors has also been shown to reduce anti-tumor effects and tumor infiltrating lymphocyte (TIL) numbers (Ashizawa et al., 2019).

Upregulation of other immune checkpoint receptors

Immune checkpoint receptors are upregulated as a compensatory mechanism after immunotherapy. These mechanisms include T cell exhaustion, proliferation, migration, and cytokine secretion by CD8+ T cells (Thommen et al., 2015; Topalian et al., 2015). Immune checkpoints such as lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin domain 3 (TIM-3), and T cell immunoreceptors with Ig and ITIM domains (TIGIT) create an immunosuppressive environment (Fig. 1, Table 1) (Toor et al., 2020). LAG-3 is expressed on TILs, and dual blockade of LAG-3 and PD-1 resulted in synergistic anti-tumor effects in preliminary models (Hellmann et al., 2016). TIM-3 was upregulated in both CD4+ and CD8+ T cells in patients with lung cancer refractory to anti–PD-1 therapy (Koyama et al., 2016). Similarly, TIGIT expression on tumor antigen-specific CD8+ T cells was observed in patients with melanoma after anti–PD-1 treatment (Chauvin et al., 2015).

Other immune checkpoint receptors such as B and T lymphocyte attenuator (BTLA), V-domain immunoglobulin-containing suppressor of T cell activation (VISTA), and sialic acid-binding Ig-like lectin 9 (SIGLEC9) are also potential treatment targets (Galon and Bruni, 2019). Similarly, immune stimulatory agents such as OX40 and inducible T cell costimulatory (ICOS) agonists enhance T cell expansion and effector functions by controlling the tumor suppressive function of regulatory T cells (Tregs) (Hu-Lieskovan and Ribas, 2017; Mahoney et al., 2015).

Suppressive tumor microenvironment

Immunosuppressive cells

In patients refractory to anti–PD-1 therapy, decreased T cell effector function is associated with an increase in immunosuppressive cells such as Tregs, myeloid-derived suppressor cells (MDSCs), and tumor associated macrophages (TAM) (Fig. 1, Table 1) (Arlauckas et al., 2017). Tregs directly inhibit effector T cells (Teff) or produce inhibitory cytokines, such as interleukin (IL)-10, IL-35, and transforming growth factor-β (TGF-β), which suppress CD8+ T cells, resulting in acquired resistance to ICIs (Sakaguchi et al., 2008; Saleh and Elkord, 2019). MDSCs induce acquired resistance to ICIs via direct action on T cells, promotion of tumor angiogenesis, and recruitment of immune suppressive cells to the tumor microenvironment (Hou et al., 2020). MDSCs in the tumor microenvironment are related to a lack of response to immunotherapy (Meyer et al., 2014). M2 macrophages reshape the tumor microenvironment into a pro-tumorigenic environment (Chanmee et al., 2014). The colony-stimulating growth factor 1 receptor (CSF1R) plays a critical role in differentiation, proliferation, and survival of the mononuclear phagocyte system and macrophages (Stanley and Chitu, 2014). Blocking CSF1R results in a decrease in tumor-associated microphages, and addition of CSF1R inhibitor with PD1 and CTLA4 antagonists improves the response to ICIs in pancreatic cancer mouse models (Zhu et al., 2014), suggesting CSF1R inhibitor as a therapeutic approach for immunotherapy resistance.

Immunosuppressive cytokines

The upregulation of the TGF-β pathway promotes the immunosuppressive effects of Tregs (Table 1) (Neel et al., 2012). Inhibition of TGF-β provided a better anti-tumor response to ICIs in a colorectal cancer model, followed by application of a TGF-β inhibitor with or without anti–CTLA-4 or radiation therapy (Fig. 1) (Hanks et al., 2014; Vanpouille-Box et al., 2015).

VEGF signaling activates the infiltration of Tregs into the tumor microenvironment and induces exhaustion of cytotoxic T lymphocytes (CTLs) by increasing inhibitory receptor expression (Voron et al., 2015). Patients with anti–PD-1 resistance have higher levels of VEGF than anti–PD-1 responsive patients (Chen et al., 2016). Combined anti-VEGF/anti–PD-L1 therapy has been shown to have beneficial outcomes in small cell lung cancer (SCLC) mouse models (Meder et al., 2018). These results suggest that the addition of VEGF inhibitors may improve the response to immunotherapy.

IL-6 and IL-8 are proinflammatory cytokines that are found in the tumor microenvironment. IL-6 decreases PD-L1 and MHC class 1 expression, leading to tumor evasion and ICI therapy resistance (Garcia-Diaz et al., 2017). IL-8 modulates chemotaxis of neutrophils, resulting in pro-tumorigenic effects (Alfaro et al., 2016). High concentrations of IL-8 inhibit T cell function and antigen presentation, thereby promoting resistance to ICI therapy (Yuen et al., 2020).

Immunoregulative molecules

Immunoregulatory molecules such as adenosine, indoleamine 2,3-dioxygenase 1 (IDO1), and B7-H4 contribute to immunosuppression, which is associated with ICI resistance (Table 1) (Platten et al., 2015; Zang et al., 2003; Zhang et al., 2004). Adenosine inhibits effector T cells and increases Tregs via adenosine A2A receptor (A2AR) binding, leading to a decrease in NK cell maturation and its action (Young et al., 2018). Blocking CD73 or A2AR prevents adenosine signaling and improves the response of tumor cells to anti–PD-1 therapy (Vijayan et al., 2017). IDO1 is an enzyme that converts tryptophan to kynurenine. Consumption of tryptophan and accumulation of kynurenine activates Teff and Tregs, and promotes Treg cell formation (Ricciuti et al., 2019). Combination of IDO inhibitors with ICI therapy enhances the TIL function and number in the tumor microenvironment (Spranger et al., 2014). B7-H4 binds to T cells and inhibits their proliferation, cytotoxic action, and interleukin secretion by T cells (Zang et al., 2003). In patients with advanced NSCLC, high expression of B7-H4 is associated with tumor progression and tumor-related death risks (Genova et al., 2019). The effect of B7-H4 on immunotherapy resistance remains to be fully elucidated.

Epigenetic modification

Epigenetic modifications are associated with anticancer immunity, including T cell function, migration, exhaustion, and neoantigen expression (Wang et al., 2020). Epigenetic modifications silence tumor suppressor and apoptosis genes, thereby activating tumor proliferation (Table 1) (Baxter et al., 2014). For instance, the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex decreases the sensitivity of tumor cells to CTLs, leading to a lack of response to immunotherapy (Miao et al., 2018; Pan et al., 2018). Several studies have demonstrated that re-invigoration of exhausted CD8+ T cells and memory T cells is feasible via chromatin remodeling and epigenetic modification (Fig. 1) (Jenkins et al., 2018; Pauken et al., 2016; Ribas et al., 2016).

POTENTIAL THERAPEUTIC STRATEGIES FOR OVERCOMING ACQUIRED RESISTANCE

Clinical trials on the IFN-γ pathway

Several clinical trials targeting JAK1/2 and STAT are ongoing. In a phase 1/2 study, AZD4205, a JAK1-selective inhibitor, was administered as both monotherapy and combination therapy with osimertinib in advanced NSCLC patients (NCT03450330). A phase 1/2 clinical trial of SC-43, an SHP-1 agonist that inhibits STAT3, in combination with cisplatin therapy for NSCLC is ongoing (NCT04733521).

Activation of stimulator of IFN genes (STING) showed an increase in anti-tumor immunity via the upregulation of proinflammatory chemokines and cytokines, including type I IFNs (Su et al., 2019). STING agonists are a promising option for patients with resistance to immunotherapy. Clinical trials of STING agonists for solid tumors, such as E7766, GSK3745417, and MIW815, are ongoing (NCT04144140, NCT03843359, and NCT03172936, respectively).

Clinical trials targeting other immune checkpoints

Randomized, double-blind, and phase 2 clinical trial of anti-TIGIT antibody tiragolumab in combination with atezolizumab (PD-L1 inhibitor) compared with placebo plus atezolizumab in patients with PD-L1-selected NSCLC (CITYSCAPE) revealed improvement in overall response rates (ORR; 31.3% for tiragolumab group and 16.2% for placebo group) and mean progression free survival (mPFS; 5.4 months for tiragolumab group and 3.6 months for placebo group) (Rodriguez-Abreu et al., 2020). Other agents targeting immune checkpoint receptors are currently under investigation (Table 2).

Clinical trials targeting tumor microenvironment

The A2AR antagonist CPI-444 showed anti-tumor effects as both monotherapy and combination therapy with atezolizumab in patients with anti–PD-1/PD-L1 treatment-refractory renal cell carcinoma (RCC) and NSCLC, with a disease control rate of 36% for monotherapy in NSCLC and 71% for combination therapy in NSCLC (Fong et al., 2017). Other agents targeting the tumor microenvironment, such as CSF1R, TGF-β, VEGF, IL-1/6, A2AR, CD73, IDO1, and B7-H4 inhibitors, are listed in Table 2.

Clinical trials on epigenetic modification

Epigenetic modifications include DNA methylation and histone (Kim et al., 2020). DNA methylation is mediated by DNA methyltransferase (DNMT), which regulates silencing of genes and non-coding genomic regions. Histone modification enzymes such as histone methyltransferase (HMT) and histone deacetylase (HDAC) change the structure of chromatin, leading to gene regulation and carcinogenesis (Kanwal and Gupta, 2012). Epigenetic modification enzyme inhibitors such as DNA methyltransferase inhibitors (DNMTis), histone methyltransferase inhibitors (HMTis), and histone deacetylase inhibitors (HDACis) are potential therapeutic targets for immunotherapy resistance (Arenas-Ramirez et al., 2018). Preclinical studies have shown that both DNMTi and HDACi increase the response to anti–PD-1 therapy in various tumors (Mazzone et al., 2017). One of the histone methyltransferase enzymes, enhancer of zeste homolog 2 (EZH2), is involved in the proliferation, migration, and invasion of various cancer cells such as glioblastoma, ovarian cancer, and prostate cancer (Yamaguchi and Hung, 2014). EZH2 exhibited a silencing effect on antigen presentation and immune reaction, and blocking of EZH2 resulted in synergistic effects with anti–CTLA-4 and IL-2 immunotherapy (Zingg et al., 2017).

For patients with relapsed or refractory malignant mesothelioma, the EZH2 inhibitor tazemetostat was well tolerated and showed a 47% disease control rate in 12 patients (Zauderer et al., 2020). A phase 1/2 clinical trial of tazemetostat monotherapy in patients with advanced solid tumors or B-cell lymphomas is currently underway (NCT01897571). Other clinical trials for epigenetic modulators such as DNMTis, HMTis, HDACis, and adoptive T cell therapy are included in Table 2.

CONCLUSION

The advent of immunotherapy has changed the treatment options in NSCLC. Prior to immunotherapy and targeted agents, chemotherapy was the backbone of treatment. Currently, the first line standard treatment for stage IV NSCLC is anti–PD-1 with or without chemotherapy, with the addition of chemotherapy depending on the PD-L1 expressions of the patients (Mok et al., 2019). There is also the option of anti–PD-L1 and VEGFR inhibitor with chemotherapy in first line non-squamous NSCLC (Socinski et al., 2018). Recently, front-line nivolumab with ipilimumab in combination with short course chemotherapy showed overall survival benefit in patients with NSCLC and received U.S. Food and Drug Administration approval (Arenas-Ramirez et al., 2018). Unprecedented results of survival gain in NSCLC have accelerated scientists and clinicians to explore various combinations of immunotherapy with other agents in order to overcome acquired resistance. Indeed, elucidating the mechanisms underlying acquired resistance is necessary to provide treatment options for this subset of patients. Notably, the upregulation IFN-γ pathway, co-inhibition of immune checkpoints such as TIGIT, and inhibition of TGF-β have gained attention as promising potential therapeutic strategies and are awaiting results.

ACKNOWLEDGMENTS

This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean Government (MSIT) (NRF-2017M3A9E9072669, 2017M3A9E8029717, NRF-2019M3A9B6065231, 2019M3A9B6065221, 2018R1A2A1A05076997, 2017R1A5A1014560).

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

CONFLICT OF INTEREST

The authors have no potential conflicts of interest to disclose.

FIGURES
Fig. 1. Immune suppressive and immune stimulatory cell-favored niche. The immune suppressive environment (left) shows the 1) immune suppressive cells including Tregs and MDSCs, 2) the expression of immune suppressive cytokines, and 3) upregulation of immune checkpoint receptors such as TIGIT, LAG-3, and TIM-3 by T cells. The immune stimulatory environment includes PD-1 expression by T cells (right). The immune suppressive cell-favored niche does not respond well to ICIs, while the immune stimulatory responds favorably to ICIs.
TABLES

Table 1

Mechanisms of acquired resistance and potential therapeutic approaches

Resistance mechanisms Description of resistance mechanisms Potential therapeutic approaches
Loss of immunogenic neoantigen Defects in IFN-γ pathway STING agonist, JAK inhibitor, STAT inhibitor
Upregulation of alternate immune checkpoint receptors Compensatory upregulation of inhibitory receptors (LAG-3, TIM-3, TIGIT, BTLA, VISTA, SIGLEC9) Blockade of alternate coinhibitory immune
checkpoint receptors: LAG-3, TIM-3, TIGIT, BTLA, VISTA, SIGLEC9
Immune stimulatory agents: OX40, ICOS
Immunosuppressive cells and immunoregulative molecules in tumor microenvironment Increased immunosuppressive cells (Treg, MDSC, M2 macrophage) CSF1R inhibitor, TGF-β inhibitor
Elevated immunosuppressive cytokines (TGF-β, VEGF, IL-6/8) TGF-β inhibitor, VEGF inhibitor, IL-1β inhibitor, IL-6/8 inhibitor
Immunoregulative molecules: adenosine pathway, IDO1, B7-H4 A2AR inhibitor/anti-CD73, IDO inhibitor, B7-H4 inhibitor
Epigenetic modification Tumor suppressor, apoptosis gene modification
Stability of chromatin remodeling complexes
Epigenetic modulators: DNMTi, HMTi, HDACi
Adoptive T cell therapy

IFN-γ, interferon-γ; STING, stimulator of IFN genes; JAK, Janus kinase; STAT, signal transducer and activators of transcription; LAG-3, lymphocyte-associated gene 3; TIM-3, T-cell immunoglobulin and mucin domain-3; TIGIT, T-cell immunoglobulin and ITIM domain; BTLA, B and T-lymphocyte attenuator; VISTA, V-domain immunoglobulin suppressor of T-cell activation; SIGLEC9, sialic acid binding Ig-like lectin 9; ICOS, inducible T-cell costimulator; Treg, regulatory T-cell; MDSC, myeloid-derived suppressor cell; CSF1R, colony stimulating factor 1 receptor; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor; IL, interleukin; IDO, indoleamine 2,3-dioxygenase; A2AR, adenosine A2A receptor; DNMTi, DNA methyltransferase inhibitor; HMTi, histone methyltransferase inhibitor; HDACi, histone deacetylase inhibitor.


Table 2

Clinical trials of investigational agents on acquired resistance

Mechanism Target Mechanism Drug Clinical trial No. Phase Tumor types Treatment arms Status
INF-γ pathway STING STING agonist E7766 NCT04144140 1 Solid tumor, lymphoma E7766 Recruiting
GSK3745417 NCT03843359 1 Solid tumor GSK3745417 ± pembrolizumab Recruiting
MIW815 NCT03172936 1 Solid tumor, lymphoma MIW815 + PDR001 Active, not recruiting
SNX281 NCT04609579 1 Solid tumor, lymphoma SNX281 ± pembrolizumab Recruiting
TAK-676 NCT04420884 1 Solid tumor TAK-676 ± pembrolizumab Recruiting
JAK JAK1 inhibitor AZD4205 NCT03450330 1,2 NSCLC AZD4205 + osimertinib Completed
Itacitinib (INCB039110) NCT03425006 2 NSCLC Itacitinib + pembrolizumab Active, not recruiting
JAK1/2 inhibitor Ruxolitinib (INCB018424) NCT02145637 1 NSCLC Ruxolitinib + afatinib Completed
STAT STAT3 inhibitor TTI-101 NCT03195699 1 Solid tumor TTI-101 Recruiting
SHP-1 agonist SC-43 NCT04733521 1,2 NSCLC, biliary tract cancer SC-43 + cisplatin Not yet recruiting
Blockade of alternate coinhibitory immune checkpoint receptors LAG-3 LAG-3 fusion protein Eftilagimod alpha (IMP321) NCT03625323 2 NSCLC, HNSCC Eftilagimodalpha + pembrolizumab Recruiting
IgG4 mAb Relatlimab (BMS-986016) NCT02750514 2 NSCLC Nivolumab ± relatlimab or ipilimumab or BMS-986205 or dasatinib Active, not recruiting
IgG4 mAb LAG525 NCT02460224 1,2 Solid tumor LAG525 ± spartalizumab (PDR001) Active, not recruiting
mAb BI 754111 NCT03780725 1 NSCLC, HNSCC BI 754111 + BI 754091 Completed
IgG4 mAb Mavezelimab (MK-4280) NCT03516981 2 NSCLC Pembrolizumab + quavonlimab or MK-4280 or lenvatinib Recruiting
TIM-3 Anti-PD-1/TIM-3 bispecific Ab RO7121661 NCT03708328 1 Solid tumor RO7121661 Recruiting
Anti-TIM-3 mAb INCAGN02390 NCT03652077 1 Solid tumor INCAGN02390 Active, not recruiting
Sym023 NCT03489343 1 Solid tumor, lymphoma Sym023 Completed
LY3321367 NCT03099109 1 Solid tumor LY3300054 (anti-PD-L1), LY3321367, LY3300054 + LY3321367 Active, not recruiting
Cobolimab (TSR-022) NCT02817633 1 Solid tumor Cobolimab ± nivolumab, cobolimab + TSR-042 ± TSR-033 or docetaxel Recruiting
Sabatolimab (MBG453) NCT02608268 1,2 Solid tumor Sabatolimab ± PDR001 or decitabine Active, not recruiting
TIGIT Anti-TIGIT mAb Tiragolumab (MTIG7192A/RG-6058) NCT04294810 3 NSCLC Atezolizumab ± tiragolumab Recruiting
NCT04256421 3 SCLC Atezolizumab + carboplatin + etoposide ± tiragolumab Recruiting
Vibostolimab (MK-7684) NCT02964013 1 Solid tumor Vibostolimab ± pembrolizumab ± pemetrexed/carboplatin, vibostolimab + carboplatin + cisplatin + etoposide Recruiting
BMS-986207 NCT02913313 1,2 Solid tumor BMS-986207 ± nivolumab Active, not recruiting
Domvanalimab (AB-154) NCT04262856 2 NSCLC Zimberelimab ± dombvanalimab ± etrumadenant Recruiting
IBI939 NCT04672356 1 NSCLC, SCLC IBI939 + sintilimab Not yet recruiting
BTLA Anti-OX40 mAb Cudarolimab (IBI101) NCT03758001 1 Solid tumor Cudarolimab ± sintilimab Recruiting
Anti-BTLA mAb TAB004 NCT04137900 1 Solid tumor TAB004 Recruiting
VISTA Anti-VISTA mAb JNJ-61610588 NCT02671955 1 Solid tumor JNJ-61610588 Terminated
CI-8993 NCT04475523 1 Solid tumor CI-8993 Recruiting
Small molecule targeting VISTA and PD-L1 CA-170 NCT02812875 1 Solid tumor, lymphoma CA-170 Completed
Immune stimulatory agents OX40 Hexavalent OX40 agonist Ab INBRX-106 NCT04198766 1 Solid tumor INBRX-106 ± pembrolizumab Recruiting
PD1-Fc-OX40L SL-279252 NCT03894618 1 Solid tumor, lymphoma SL-279252 Recruiting
Anti-OX40 agonist mAb PF-04518600 NCT02315066 1 Solid cancer PF-04518600 ± PF-05082566 Completed
INCAGN01949 NCT02923349 1,2 Solid tumor INCAGN01949 Completed
ICOS Anti-ICOS mAb GSK3359609 NCT03693612 2 Solid tumor GSK3359609 + tremelimumab, docetaxel + paclitaxel + cetuximab Recruiting
JTX-2011 NCT02904226 1,2 Solid tumor JTX-2011 + pembrolizumab or nivolumab or ipilimumab Completed
KY1044 NCT03829501 1,2 Solid tumor KY1044 ± atezolizumab Completed
Tumor microenvironment CSF1R MET, CSF1R, SRC kinase inhibitor TPX-0022 NCT03993873 1 Solid tumor TPX-0022 Recruiting
CSF1R mAb Cabiralizumab (FPA008) NCT02526017 1 Solid tumor FPA008 + BMS-936558 Completed
TGF-b TGF-bR inhibitor Galunisertib (LY2157299) NCT02423343 1,2 Solid tumor Galunisertib + nivolumab Completed
TEW 7197 NCT02160106 1 Solid tumor TEW-7197 Completed
TGF-b inhibitor AVID200 NCT03834662 1 Solid tumor AVID200 Active, not recruiting
Anti-TGF-bmAb SAR-439459 NCT04729725 1 Solid tumor SAR-439459 + cemiplimab Not yet recruiting
VEGF VEGFR TKI inhibitor Vandetanib (ZD6474) NCT00418886 3 NSCLC Vandetanib + pemetrexed Active, not recruiting
Axitinib (AG-013736) NCT03472560 2 NSCLC, urothelial cancer Axitinib + avelumab Active, not recruiting
Apatinib (YN968D1) NCT03389256 2 EGFR T790M-negative NSCLC Apatinib + EGFR-TKI Not yet recruiting
Anti-VEGF mAb Bevacizumab (L01XC07) NCT00451906 3 NSCLC Bevacizumab + first-line chemotherapy Completed
IBI305 NCT03802240 3 Non-squamous NSCLC Sintilimab ± IBI305 + pemetrexed + cisplatin Recruiting
Anti-VEGFR mAb Ramucirumab (LY3009806) NCT04340882 2 NSCLC Ramucirumab + docetaxel + pembrolizumab Recruiting
Aurora B/VEGFR/PDGFR/c-Kit/CSF1R inhibitor Chiauranib (CS2164) NCT03216343 1 SCLC Chiauranib Recruiting
IL-1b Anti-IL-1b mAb Canakinumab (ACZ885) NCT03626545 3 NSCLC Canakinumab + docetaxel Active, not recruiting
IL1RAP Ab CAN04 NCT04452214 1 Solid tumor CAN04 + pembrolizumab Recruiting
IL-6 Anti-IL-6R mAb Tocilizumab (RO4877533) NCT04691817 1,2 NSCLC Tocilizumab + atezolizumab Not yet recruiting
Anti-IL-6 mAb Siltuximab (CNTO 328) NCT00841191 1,2 Solid tumor Siltuximab Completed
IL-8 Anti-IL-8 mAb BMS-986253 NCT04123379 2 NSCLC, HCC Nivolumab + BMS-813160 or BMS-986253 Recruiting
Tumor microenvironment A2AR A2AR antagonist PBF-509 NCT02403193 1,2 NSCLC PBF-509 + PDR001 Active, not recruiting
Etrumadenant (AB928) NCT03846310 1 Lung cancer Etrumadenant + carboplatin + pemetrexed Recruiting
CD73 Small molecule CD73 inhibitor LY3475070 NCT04148937 1 Solid tumor LY3475070 ± pembrolizumab Recruiting
Anti-CD73 mAb CPI-006 NCT03454451 1 Solid cancer, NHL CPI-006 ± ciforadenant or pembrolizumab Recruiting
Oleclumab (MEDI9447) NCT03381274 1,2 EGFR-mutant NSCLC MEDI9447 + osimertinib or AZD4635 Active, not recruiting
Sym024 NCT04672434 1 Solid tumor Sym021 ± Sym024 Recruiting
NZV930 NCT03549000 1 Solid tumor NZV930 ± PDR001 ± NIR178 Recruiting
IDO1 IDO inhibitor Indoximod (NLG-8189) NCT02460367 1 NSCLC Indoximod + docetaxel + tergenpumatucel-L Active, not recruiting
B7-H4 B7-H4 Ab FPA150 NCT03514121 1 Solid tumor FPA150 + pembrolizumab Active, not recruiting
Epigenetic modulators Hypomethylating agents DNMTi Guadecitabine (SGI-110) NCT03913455 2 SCLC Guadecitabine + carboplatin Active, not recruiting
Cytidine nucleoside analogue CC-486 NCT02546986 2 NSCLC Pembrolizumab ± CC-486 Active, not recruiting
Deoxycitidine analogue Aza-TdCyd NCT03366116 1 Solid tumor Aza-TdCyd Recruiting
HMTi EZH2 inhibitor Tazemetostat (EPZ-6438) NCT01897571 1,2 Solid tumor, B-cell lymphoma Tazemetostat Active, not recruiting
HDACi HDAC inhibitor ACY-241 NCT02635061 1 NSCLC ACY-241 + nivolumab Active, not recruiting
Mocetinostat (MGCD01013) NCT02954991 2 NSCLC Nivolumab + glesatinib or sitravatinib or mocetinostat Active, not recruiting
Entinostat (SNDX-275) NCT01928576 2 NSCLC Entinostat + azacitidine + nivolumab Recruiting
Vorinostat (MK0683) NCT02638090 1,2 NSCLC Pembrolizumab ± vorinostat Recruiting
Abexinostat (PCI-24781) NCT03590054 1 Solid tumor Abexinostat + pembrolizumab Recruiting
Adoptive T cell therapy Genetically modified T cells NCT02408016 1,2 NSCLC, mesothelioma Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes Active, not recruiting
Genetically modified T cells NCT02706392 1 ROR1-positive Solid tumor ROR1 CAR-specific autologous T-Lymphocytes Recruiting

STING, stimulator of IFN genes; JAK, Janus kinase; NSCLC, non-small cell lung cancer; STAT, signal transducer and activators of transcription; SHP-1, Src-homology2 domain-containing phosphatase-1; LAG-3, lymphocyte-associated gene 3; HNSCC, head and neck squamous cell carcinoma; TIM-3, T-cell immunoglobulin and mucin domain-3; anti-PD-L1, anti-programmed cell death ligand 1; TIGIT, T-cell immunoglobulin and ITIM domain; SCLC, small cell lung cancer; BTLA, B and T-lymphocyte attenuator; VISTA, V-domain immunoglobulin suppressor of T-cell activation; ICOS, inducible T-cell costimulator; CSF1R, colony stimulating factor 1 receptor; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor; IL, interleukin; Anti-IL-6R-mAb, anti-interleukin-6 receptor monoclonal antibody; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; HCC, hepatocellular carcinoma; A2AR, adenosine A2A receptor; NHL, non-Hodgkin lymphoma; IDO, indoleamine 2,3-dioxygenase; DNMTi, indoleamine 2,3-dioxygenase; HMTi, histone methyltransferase inhibitor; HDACi, histone deacetylase inhibitor; ROR1, tyrosine-protein kinase transmembrane receptor.


REFERENCES
  1. Abiko K., Matsumura N., Hamanishi J., Horikawa N., Murakami R., Yamaguchi K., Yoshioka Y., Baba T., Konishi I., and Mandai M. (2015). IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501-1509.
    Pubmed KoreaMed CrossRef
  2. Alfaro C., Teijeira A., Oñate C., Pérez G., Sanmamed M.F., Andueza M.P., Alignani D., Labiano S., Azpilikueta A., and Rodriguez-Paulete A., et al. (2016). Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin. Cancer Res. 22, 3924-3936.
    Pubmed CrossRef
  3. Arenas-Ramirez N., Sahin D., and Boyman O. (2018). Epigenetic mechanisms of tumor resistance to immunotherapy. Cell. Mol. Life Sci. 75, 4163-4176.
    Pubmed CrossRef
  4. Arlauckas S.P., Garris C.S., Kohler R.H., Kitaoka M., Cuccarese M.F., Yang K.S., Miller M.A., Carlson J.C., Freeman G.J., and Anthony R.M., et al. (2017). In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9, eaal3604.
    Pubmed KoreaMed CrossRef
  5. Ashizawa T., Iizuka A., Maeda C., Tanaka E., Kondou R., Miyata H., Sugino T., Kawata T., Deguchi S., and Mitsuya K., et al. (2019). Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. Immunol. Lett. 216, 43-50.
    Pubmed CrossRef
  6. Bach E.A., Aguet M., and Schreiber R.D. (1997). The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563-591.
  7. Bagchi S., Yuan R., and Engleman E.G. (2021). Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223-249.
    Pubmed CrossRef
  8. Baxter E., Windloch K., Gannon F., and Lee J.S. (2014). Epigenetic regulation in cancer progression. Cell Biosci. 4, 45.
    Pubmed KoreaMed CrossRef
  9. Chanmee T., Ontong P., Konno K., and Itano N. (2014). Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6, 1670-1690.
    Pubmed KoreaMed CrossRef
  10. Chauvin J.M., Pagliano O., Fourcade J., Sun Z., Wang H., Sander C., Kirkwood J.M., Chen T.H., Maurer M., and Korman A.J., et al. (2015). TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J. Clin. Invest. 125, 2046-2058.
  11. Chen P.L., Roh W., Reuben A., Cooper Z.A., Spencer C.N., Prieto P.A., Miller J.P., Bassett R.L., Gopalakrishnan V., and Wani K., et al. (2016). Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827-837.
    Pubmed KoreaMed CrossRef
  12. Ettinger D.S., Wood D.E., Aggarwal C., Aisner D.L., Akerley W., Bauman J.R., Bharat A., Bruno D.S., Chang J.Y., and Chirieac L.R., et al. (2019). NCCN guidelines insights: non-small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 17, 1464-1472.
  13. Fong L., Forde P.M., Powderly J.D., Goldman J.W., Nemunaitis J.J., Luke J.J., Hellmann M.D., Kummar S., Doebele R.C., and Mahadevan D., et al. (2017). Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. 35(15 Suppl), 3004.
  14. Galon J. and Bruni D. (2019). Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197-218.
    Pubmed CrossRef
  15. Garcia-Diaz A., Shin D.S., Moreno B.H., Saco J., Escuin-Ordinas H., Rodriguez G.A., Zaretsky J.M., Sun L., Hugo W., and Wang X., et al. (2017). Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189-1201.
    Pubmed KoreaMed CrossRef
  16. Genova C., Boccardo S., Mora M., Rijavec E., Biello F., Rossi G., Tagliamento M., Dal Bello M.G., Coco S., and Alama A., et al. (2019). Correlation between B7-H4 and survival of non-small-cell lung cancer patients treated with nivolumab. J. Clin. Med. 8, 1566.
    Pubmed KoreaMed CrossRef
  17. Gettinger S., Choi J., Hastings K., Truini A., Datar I., Sowell R., Wurtz A., Dong W., Cai G., and Melnick M.A., et al. (2017). Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 7, 1420-1435.
    Pubmed KoreaMed CrossRef
  18. Hanks B.A., Holtzhausen A., Evans K., Heid M., and Blobe G.C. (2014). Combinatorial TGF-β signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAFV600E-PTEN-/- transgenic model of melanoma. J. Clin. Oncol. 32(15 Suppl), 3011.
  19. Hellmann M.D., Friedman C.F., and Wolchok J.D. (2016). Combinatorial cancer immunotherapies. Adv. Immunol. 130, 251-277.
    Pubmed CrossRef
  20. Hou A., Hou K., Huang Q., Lei Y., and Chen W. (2020). Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Front. Immunol. 11, 783.
    Pubmed KoreaMed CrossRef
  21. Hu-Lieskovan S. and Ribas A. (2017). New combination strategies using PD-1/L1 checkpoint inhibitors as a backbone. Cancer J. 23, 10-22.
  22. Jenkins R.W., Barbie D.A., and Flaherty K.T. (2018). Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9-16.
    Pubmed KoreaMed CrossRef
  23. Kanwal R. and Gupta S. (2012). Epigenetic modifications in cancer. Clin. Genet. 81, 303-311.
    Pubmed KoreaMed CrossRef
  24. Kim D., Lee Y.S., Kim D.H., and Bae S.C. (2020). Lung cancer staging and associated genetic and epigenetic events. Mol. Cells 43, 1-9.
    Pubmed KoreaMed CrossRef
  25. Koyama S., Akbay E.A., Li Y.Y., Herter-Sprie G.S., Buczkowski K.A., Richards W.G., Gandhi L., Redig A.J., Rodig S.J., and Asahina H., et al. (2016). Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501.
    Pubmed KoreaMed CrossRef
  26. Mahoney K.M., Rennert P.D., and Freeman G.J. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561-584.
    Pubmed CrossRef
  27. Manguso R.T., Pope H.W., Zimmer M.D., Brown F.D., Yates K.B., Miller B.C., Collins N.B., Bi K., LaFleur M.W., and Juneja V.R., et al. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413-418.
    Pubmed KoreaMed CrossRef
  28. (2018). TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544-548.
    Pubmed KoreaMed CrossRef
  29. Mazzone R., Zwergel C., Mai A., and Valente S. (2017). Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin. Epigenetics 9, 59.
    Pubmed KoreaMed CrossRef
  30. Meder L., Schuldt P., Thelen M., Schmitt A., Dietlein F., Klein S., Borchmann S., Wennhold K., Vlasic I., and Oberbeck S., et al. (2018). Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res. 78, 4270-4281.
    Pubmed CrossRef
  31. Meyer C., Cagnon L., Costa-Nunes C.M., Baumgaertner P., Montandon N., Leyvraz L., Michielin O., Romano E., and Speiser D.E. (2014). Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247-257.
    Pubmed CrossRef
  32. Miao D., Margolis C.A., Gao W., Voss M.H., Li W., Martini D.J., Norton C., Bossé D., Wankowicz S.M., and Cullen D., et al. (2018). Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801-806.
    Pubmed KoreaMed CrossRef
  33. Mok T.S.K., Wu Y.L., Kudaba I., Kowalski D.M., Cho B.C., Turna H.Z., Castro G. Jr., Srimuninnimit V. Jr., Laktionov K.K. Jr., and Bondarenko I. Jr., et al. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819-1830.
    Pubmed CrossRef
  34. Neel J.C., Humbert L., and Lebrun J.J. (2012). The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. ISRN Mol. Biol. 2012, 381428.
    Pubmed KoreaMed CrossRef
  35. Pan D., Kobayashi A., Jiang P., Ferrari, de Andrade L., Tay R.E., Luoma A.M., Tsoucas D., Qiu X., Lim K., and Rao P., et al. (2018). A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770-775.
    Pubmed KoreaMed CrossRef
  36. Pauken K.E., Sammons M.A., Odorizzi P.M., Manne S., Godec J., Khan O., Drake A.M., Chen Z., Sen D.R., and Kurachi M., et al. (2016). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160-1165.
    Pubmed KoreaMed CrossRef
  37. Peng W., Chen J.Q., Liu C., Malu S., Creasy C., Tetzlaff M.T., Xu C., McKenzie J.A., Zhang C., and Liang X., et al. (2016). Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202-216.
    Pubmed KoreaMed CrossRef
  38. Pereira C., Gimenez-Xavier P., Pros E., Pajares M.J., Moro M., Gomez A., Navarro A., Condom E., Moran S., and Gomez-Lopez G., et al. (2017). Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition. Clin. Cancer Res. 23, 3203-3213.
    Pubmed CrossRef
  39. Platten M., von Knebel Doeberitz N., Oezen I., Wick W., and Ochs K. (2015). Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front. Immunol. 5, 673.
    Pubmed KoreaMed CrossRef
  40. Pourmir I., Gazeau B., de Saint Basile H., and Fabre E. (2020). Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality? Cancer Drug Resist. 3, 276-286.
  41. Remon J., Passiglia F., Ahn M.J., Barlesi F., Forde P.M., Garon E.B., Gettinger S., Goldberg S.B., Herbst R.S., and Horn L., et al. (2020). Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J. Thorac. Oncol. 15, 914-947.
    Pubmed CrossRef
  42. Ren D., Hua Y., Yu B., Ye X., He Z., Li C., Wang J., Mo Y., Wei X., and Chen Y., et al. (2020). Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol. Cancer 19, 19.
    Pubmed KoreaMed CrossRef
  43. Ribas A., Shin D.S., Zaretsky J., Frederiksen J., Cornish A., Avramis E., Seja E., Kivork C., Siebert J., and Kaplan-Lefko P., et al. (2016). PD-1 blockade expands intratumoral memory T cells. Cancer Immunol. Res. 4, 194-203.
    Pubmed KoreaMed CrossRef
  44. Ricciuti B., Leonardi G.C., Puccetti P., Fallarino F., Bianconi V., Sahebkar A., Baglivo S., Chiari R., and Pirro M. (2019). Targeting indoleamine-2, 3-dioxygenase in cancer: scientific rationale and clinical evidence. Pharmacol. Ther. 196, 105-116.
    Pubmed CrossRef
  45. Rodriguez-Abreu D., Johnson M.L., Hussein M.A., Cobo M., Patel A.J., Secen N.M., Lee K.H., Massuti B., Hiret S., and Yang J.C.H., et al. (2020). Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J. Clin. Oncol. 38(15 Suppl), 9503.
  46. Sakaguchi S., Yamaguchi T., Nomura T., and Ono M. (2008). Regulatory T cells and immune tolerance. Cell 133, 775-787.
    Pubmed CrossRef
  47. Saleh R. and Elkord E. (2019). Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 457, 168-179.
    Pubmed CrossRef
  48. Sharma P., Hu-Lieskovan S., Wargo J.A., and Ribas A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707-723.
    Pubmed KoreaMed CrossRef
  49. Shin D.S., Zaretsky J.M., Escuin-Ordinas H., Garcia-Diaz A., Hu-Lieskovan S., Kalbasi A., Grasso C.S., Hugo W., Sandoval S., and Torrejon D.Y., et al. (2017). Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188-201.
    Pubmed KoreaMed CrossRef
  50. Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., Thomas C.A., and Barlesi F., et al. (2018). Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288-2301.
    Pubmed CrossRef
  51. Spranger S., Koblish H.K., Horton B., Scherle P.A., Newton R., and Gajewski T.F. (2014). Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J. Immunother. Cancer 2, 3.
    Pubmed KoreaMed CrossRef
  52. Stanley E.R. and Chitu V. (2014). CSF-1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 6, a021857.
    Pubmed KoreaMed CrossRef
  53. Steven A., Fisher S.A., and Robinson B.W. (2016). Immunotherapy for lung cancer. Respirology 21, 821-833.
    Pubmed CrossRef
  54. Su T., Zhang Y., Valerie K., Wang X.Y., Lin S., and Zhu G. (2019). STING activation in cancer immunotherapy. Theranostics 9, 7759-7771.
    Pubmed KoreaMed CrossRef
  55. Sucker A., Zhao F., Pieper N., Heeke C., Maltaner R., Stadtler N., Real B., Bielefeld N., Howe S., and Weide B., et al. (2017). Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat. Commun. 8, 15440.
    Pubmed KoreaMed CrossRef
  56. Sucker A., Zhao F., Real B., Heeke C., Bielefeld N., Maβen S., Horn S., Moll I., Maltaner R., and Horn P.A., et al. (2014). Genetic evolution of T-cell resistance in the course of melanoma progression. Clin. Cancer Res. 20, 6593-6604.
    Pubmed CrossRef
  57. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., Chen S., Klein A.P., Pardoll D.M., and Topalian S.L., et al. (2012). Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra37.
    Pubmed KoreaMed CrossRef
  58. Thommen D.S., Schreiner J., Müller P., Herzig P., Roller A., Belousov A., Umana P., Pisa P., Klein C., and Bacac M., et al. (2015). Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol. Res. 3, 1344-1355.
    Pubmed CrossRef
  59. Toor S.M., Nair V.S., Decock J., and Elkord E. (2020). Immune checkpoints in the tumor microenvironment. Semin. Cancer Biol. 65, 1-12.
    Pubmed CrossRef
  60. Topalian S.L., Drake C.G., and Pardoll D.M. (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461.
    Pubmed KoreaMed CrossRef
  61. Toso A., Revandkar A., Di Mitri D., Guccini I., Proietti M., Sarti M., Pinton S., Zhang J., Kalathur M., and Civenni G., et al. (2014). Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9, 75-89.
    Pubmed CrossRef
  62. Vanpouille-Box C., Diamond J.M., Pilones K.A., Zavadil J., Babb J.S., Formenti S.C., Barcellos-Hoff M.H., and Demaria S. (2015). TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75, 2232-2242.
    Pubmed KoreaMed CrossRef
  63. Vijayan D., Young A., Teng M.W., and Smyth M.J. (2017). Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17, 709-724.
    Pubmed CrossRef
  64. Voron T., Colussi O., Marcheteau E., Pernot S., Nizard M., Pointet A.L., Latreche S., Bergaya S., Benhamouda N., and Tanchot C., et al. (2015). VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 212, 139-148.
    Pubmed KoreaMed CrossRef
  65. Wang F., Wang S., and Zhou Q. (2020). The resistance mechanisms of lung cancer immunotherapy. Front. Oncol. 10, 568059.
    Pubmed KoreaMed CrossRef
  66. Xu L.J., Ma Q., Zhu J., Li J., Xue B.X., Gao J., Sun C.Y., Zang Y.C., Zhou Y.B., and Yang D.R., et al. (2018). Combined inhibition of JAK1, 2/Stat3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia. Mol. Med. Rep. 17, 8111-8120.
    KoreaMed CrossRef
  67. Yamaguchi H. and Hung M.C. (2014). Regulation and role of EZH2 in cancer. Cancer Res. Treat. 46, 209-222.
    Pubmed KoreaMed CrossRef
  68. Young A., Ngiow S.F., Gao Y., Patch A.M., Barkauskas D.S., Messaoudene M., Lin G., Coudert J.D., Stannard K.A., and Zitvogel L., et al. (2018). A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 78, 1003-1016.
    Pubmed CrossRef
  69. Yuen K.C., Liu L.F., Gupta V., Madireddi S., Keerthivasan S., Li C., Rishipathak D., Williams P., Kadel E.E. 3rd, and Koeppen H. 3rd, et al. (2020). High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat. Med. 26, 693-698.
    Pubmed CrossRef
  70. Zang X., Loke P., Kim J., Murphy K., Waitz R., and Allison J.P. (2003). B7x: a widely expressed B7 family member that inhibits t cell activation. Proc. Natl. Acad. Sci. U. S. A. 100, 10388-10392.
    Pubmed KoreaMed CrossRef
  71. Zaretsky J.M., Garcia-Diaz A., Shin D.S., Escuin-Ordinas H., Hugo W., Hu-Lieskovan S., Torrejon D.Y., Abril-Rodriguez G., Sandoval S., and Barthly L., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829.
    Pubmed KoreaMed CrossRef
  72. Zauderer M.G., Szlosarek P.W., Le Moulec S., Popat S., Taylor P., Planchard D., Scherpereel A., Jahan T.M., Koczywas M., and Forster M., et al. (2020). Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma. J. Clin. Oncol. 38(15 Suppl), 9058.
  73. Zhang H., Conrad D.M., Butler J.J., Zhao C., Blay J., and Hoskin D.W. (2004). Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3′, 5′-monophosphate and phosphatases. J. Immunol. 173, 932-944.
  74. Zhu Y., Knolhoff B.L., Meyer M.A., Nywening T.M., West B.L., Luo J., Wang-Gillam A., Goedegebuure S.P., Linehan D.C., and DeNardo D.G. (2014). CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057-5069.
    Pubmed KoreaMed CrossRef
  75. Zingg D., Arenas-Ramirez N., Sahin D., Rosalia R.A., Antunes A.T., Haeusel J., Sommer L., and Boyman O. (2017). The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 20, 854-867.
    Pubmed CrossRef


Current Issue

30 September 2021 Volume 44,
Number 9, pp. 627~698
COVER PICTURE Non-mitochondrial localization of the N-terminal-deleted mutant form of ACSL1 in Cos7 cells. Green, ACSL1 mutant; Red, mitotracker; Blue, DAPI (Nan et al., pp. 637-646).

This Article


Cited By Articles
  • CrossRef (0)

Social Network Service
Services

Indexed in

  • Science Central
  • CrossMark